Trial Details
Trial status:
In follow-up (non-recruiting)
Recruitment start date:
01/10/2003
Funder:
Leukaemia Research Fund
Sponsor:
The Christie NHS Foundation Trust
Chief Investigator:
Professor John Radford
Recruitment target:
400
EudraCT number:
N/A
Contact details:
ctc.FDG-PET@ucl.ac.uk
Lay summary:
RAPID
A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin’s Disease
Description
Design: A randomised (1:1), multicentre, phase III trial to determine whether patients with clinical stage IA/IIA Hodgkin’s disease who have a negative FDG-PET scan after 3 cycles of ABVD require consolidation radiotherapy to areas of previous involvement in order to delay or prevent disease progression.
Treatment: Patients with early stage, low risk Hodgkin’s disease will receive 3 cycles of ABVD chemotherapy followed by FDG-PET imaging.  Individuals who are PET positive will receive a further (4th) cycle of ABVD followed by involved field radiotherapy.  Those who are PET negative will be randomised to receive either involved field RT or no further treatment. All patients will then be followed up uniformly with surveillance CT scans at 6, 12 and 24 months.  
Key inclusion/exclusion criteria:
Inclusion criteria
  • Age 16-75 years
  • Histologically confirmed Hodgkin’s disease 
  • Clinical stages IA/IIA above the diaphragm with no mediastinal bulk (defined as maximum transverse diameter of mediastinal mass: internal thoracic diameter at level of D5/6 interspace >0.33). Bulky disease at other sites (defined as nodal mass with transverse diameter >10 cm) is acceptable.
  • No previous treatment for Hodgkin’s disease
  • No previous malignancy (with exceptions)
  • No contraindications to chemotherapy or radiotherapy

Exclusion criteria
  • Patients with clinical stage IA Hodgkin’s disease with no clinical or CT evidence of disease after diagnostic biopsy
  • Pregnant or lactating women
  • Severe underlying illness considered likely to make the trial therapy hazardous 

Duration of recruitment: 7 years
Aim
To determine whether patients with clinical stage IA/IIA Hodgkin’s disease who have a negative FDG-PET scan after 3 cycles of ABVD require consolidation radiotherapy to areas of previous involvement in order to delay or prevent disease progression.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2018 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us